AC
LENZ

Annandale Capital’s LENZ Therapeutics LENZ Stock Holding History

Annandale Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,561
Closed -$47K – 147
2023
Q2 		$47K Hold
2,561
– – 0.01% 135
2023
Q1 		$44K Hold
2,561
– – 0.01% 131
2022
Q4 		$60K Buy
+2,561
New +$59.4K 0.02% 129

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Annandale Capital's LENZ Position: Q3 2023 in Review

Annandale Capital sold out of LENZ Therapeutics (LENZ) in Q3 2023, closing a stake of 2,561 shares — an estimated $47K sold.

Annandale Capital first reported a position in LENZ in Q4 2022 and held it in 3 quarters. The position peaked at $60K in Q4 2022. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • Annandale Capital reported no remaining LENZ Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Annandale Capital sold 2,561 LENZ Therapeutics shares in Q3 2023, an estimated $47K.
  • Annandale Capital first reported a position in LENZ Therapeutics in Q4 2022 and held it in 3 quarters.
  • Annandale Capital's LENZ Therapeutics position peaked at $60K in Q4 2022.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on Annandale Capital's 13F filing for Q3 2023, filed 15 Nov 2023.